Early work has shown that the PKC inhibitor ENZA could have a direct effect on MM cells [56], either by preventing the phosphorylation of β-catenin and its degradation in the proteasome and, therefore, its accumulation, or by inhibiting Akt and inducing apoptosis [57,58]. This evidence concerns the gene AKT1 and Miyoshi myopathy.